<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE MedlineCitationSet PUBLIC "-//NLM//DTD Medline Citation, 1st January, 2013//EN"
                                    "http://www.nlm.nih.gov/databases/dtd/nlmmedlinecitationset_130101.dtd">
<MedlineCitationSet>
<MedlineCitation Owner="NLM" Status="In-Data-Review">
<PMID Version="1">23419111</PMID>
<DateCreated>
<Year>2013</Year>
<Month>02</Month>
<Day>19</Day>
</DateCreated>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1365-2516</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>19</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Haemophilia : the official journal of the World Federation of Hemophilia</Title>
<ISOAbbreviation>Haemophilia</ISOAbbreviation>
</Journal>
<ArticleTitle>An unusual clinical manifestation in a factor IX deficient patient: orbital haemorrhage without trauma.</ArticleTitle>
<Pagination>
<MedlinePgn>e99-e100</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/hae.12088</ELocationID>
<Affiliation>Hematology, Eskişehir Osmangazi University Medical Faculty, Eskişehir, Turkey.</Affiliation>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Teke</LastName>
<ForeName>H Ü</ForeName>
<Initials>HÜ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Akay</LastName>
<ForeName>O M</ForeName>
<Initials>OM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gündüz</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tokmak</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Saylisoy</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Haemophilia</MedlineTA>
<NlmUniqueID>9442916</NlmUniqueID>
<ISSNLinking>1351-8216</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="In-Data-Review">
<PMID Version="1">23009387</PMID>
<DateCreated>
<Year>2013</Year>
<Month>02</Month>
<Day>19</Day>
</DateCreated>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">2191-1991</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2012</Year>
</PubDate>
</JournalIssue>
<Title>Health economics review</Title>
<ISOAbbreviation>Health Econ Rev</ISOAbbreviation>
</Journal>
<ArticleTitle>Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model.</ArticleTitle>
<Pagination>
<MedlinePgn>19</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/2191-1991-2-19</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">ABSTRACT:</AbstractText>
<AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Persistent infections with human papillomavirus (HPV) are a necessary cause of cervical cancer and are responsible for important morbidity in men and women. Since 2007, HPV vaccination has been recommended and funded for all girls aged 12 to 17 in Germany. A previously published cost-effectiveness analysis, using a static model, showed that a quadrivalent HPV vaccination programme for 12-year-old girls in Germany would be cost effective. Here we present the results from a dynamic transmission model that can be used to evaluate the impact and cost-effectiveness of different vaccination schemas.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We adapted a HPV dynamic transmission model, which has been used in other countries, to the German context. The model was used to compare a cervical cancer screening only strategy with a strategy of combining vaccination of females aged 12-17 years old and cervical cancer screening, based on the current recommendations in Germany. In addition, the impact of increasing vaccination coverage in this cohort of females aged 12-17 years old was evaluated in sensitivity analysis.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The results from this analysis show that the current quadrivalent HPV vaccination programme of females ages 12 to 17 in Germany is cost-effective with an ICER of 5,525€/QALY (quality adjusted life year). The incremental cost-effectiveness ratio (ICER) increased to 10,293€/QALY when the vaccine effects on HPV6/11 diseases were excluded. At steady state, the model predicted that vaccinating girls aged 12 to 17 could reduce the number of HPV 6/11/16/18-related cervical cancers by 65% and genital warts among women and men by 70% and 48%, respectively. The impact on HPV-related disease incidence and costs avoided would occur relatively soon after initiating the vaccine programme, with much of the early impact being due to the prevention of HPV6/11-related genital warts.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results show that the current quadrivalent HPV vaccination and cervical cancer screening programmes in Germany will substantially reduce the incidence of cervical cancer, cervical intraepithelial neoplasia (CIN) and genital warts. The evaluated vaccination strategies were all found to be cost-effective. Future analyses should include more HPV-related diseases.</AbstractText>
</Abstract>
<Affiliation>Market Access, Vaccine Advocacy &amp; Medical Affairs, Sanofi Pasteur MSD, 8 rue Jonas Salk, 69007, Lyon, France. ECretin-Maitenaz@spmsd.com.</Affiliation>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Schobert</LastName>
<ForeName>Deniz</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Remy</LastName>
<ForeName>Vanessa</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schoeffski</LastName>
<ForeName>Oliver</ForeName>
<Initials>O</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2012</Year>
<Month>09</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Health Econ Rev</MedlineTA>
<NlmUniqueID>101583209</NlmUniqueID>
</MedlineJournalInfo>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="In-Data-Review">
<PMID Version="1">23227908</PMID>
<DateCreated>
<Year>2013</Year>
<Month>02</Month>
<Day>19</Day>
</DateCreated>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-7525</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>10</Volume>
<PubDate>
<Year>2012</Year>
</PubDate>
</JournalIssue>
<Title>Health and quality of life outcomes</Title>
<ISOAbbreviation>Health Qual Life Outcomes</ISOAbbreviation>
</Journal>
<ArticleTitle>Screening for depressed mood in an adolescent psychiatric context by brief self-assessment scales - testing psychometric validity of WHO-5 and BDI-6 indices by latent trait analyses.</ArticleTitle>
<Pagination>
<MedlinePgn>149</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1477-7525-10-149</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">ABSTRACT:</AbstractText>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Major depressive disorder is prevalent in the adolescent psychiatric clinical setting and often comorbid with other primary psychiatric diagnoses such as ADHD or social anxiety disorder. Systematic manual-based diagnostic procedures are recommended to identify such comorbidity but they are time-consuming and often not fully implemented in clinical practice. Screening for depressive symptoms in the child psychiatric context using brief, user-friendly and easily managed self-assessment scales may be of clinical value and utility. The aim of the study is to test the psychometric validity of two such scales, which may be used in a two-step screening procedure, the WHO-Five Well-being Index (WHO-5) and the six-item version of Beck's Depression Inventory (BDI-6).</AbstractText>
<AbstractText Label="METHOD" NlmCategory="METHODS">66 adolescent psychiatric patients with a clinical diagnosis of major depressive disorder (MDD), 60 girls and 6 boys, aged 14-18 years, mean age 16.8 years, completed the WHO-5 scale as well as the BDI-6. Statistical validity was tested by Mokken and Rasch analyses.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The correlation between WHO-5 and BDI-6 was -0.49 (p=0.0001). Mokken analyses showed a coefficient of homogeneity for the WHO-5 of 0.52 and for the BDI-6 of 0.46. Rasch analysis also accepted unidimensionality when testing males versus females (p &gt; 0.05).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The WHO-5 is psychometrically valid in an adolescent psychiatric context including both genders to assess the wellness dimension and applicable as a first step in screening for MDD. The BDI-6 may be recommended as a second step in the screening procedure, since it is statistically valid and has the ability to unidimensionally capture the severity of depressed mood.</AbstractText>
</Abstract>
<Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Retzius väg 8, A2:3, Stockholm, 17177, Sweden. eva.henjeblom@ki.se.</Affiliation>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Blom</LastName>
<ForeName>Eva Henje</ForeName>
<Initials>EH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bech</LastName>
<ForeName>Per</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Högberg</LastName>
<ForeName>Göran</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Larsson</LastName>
<ForeName>Jan Olov</ForeName>
<Initials>JO</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Serlachius</LastName>
<ForeName>Eva</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2012</Year>
<Month>12</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Health Qual Life Outcomes</MedlineTA>
<NlmUniqueID>101153626</NlmUniqueID>
<ISSNLinking>1477-7525</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
</MedlineCitation>



</MedlineCitationSet>